NEW YORK (GenomeWeb) – Myriad Genetics today said it and BioMarin Pharmaceutical have expanded their collaboration to use Myriad's companion diagnostic test to identify patients who may benefit from the anti-cancer drug talazoparib.
Under the terms of the agreement, BioMarin will use Myriad's myChoice HRD test to identify patients with metastatic breast, ovarian, and potentially other tumor types who may be candidates for talazoparib, an investigational poly-ADP ribose polymerase inhibitor under development by BioMarin. The companies will collaborate under US Food and Drug Administration regulations and guidelines to develop and possibly seek regulatory approval of talazoparib and myChoice HRD.
Financial and other terms were not disclosed.
Today's deal builds on a relationship between Myriad and BioMarin started in 2013 when they reached a deal for the use of Myriad's BRACAnalysis CDx in the pivotal Phase III EMBRACA and Phase II ABRAZO clinical study of talazoparib for advanced or metastatic breast cancer patients with BRCA mutations.